Thus, enlightening the insulin/IGF-driven interaction between cancer cells, endocrine pancreas, and the stroma may be key to understanding the progression of PDAC and of PDAC-associated diabetes, and thereby open the door to the development of efficent therapies that target cancer cells and tumor stroma at the same time. The gene discussed is INS; the disease is cancer.